trial
as of 2026-07-017-week Study With CT-155 in People With Schizophrenia
NCTId NCT05486312
at a glance
— · Completed
Enrollment 72 (actual)
Sponsored by Click Therapeutics, Inc.
Primary completion 2022-09-22
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Completed
Enrollment
72 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2022-07-05
Primary completion
2022-09-22
Eligibility
ALL · 18 Years · 64 Years
Interventions & indications
Indications
Sponsors
Click Therapeutics, Inc.Lead Sponsor
Investigators
1
Shaheen Lakhan, MDPhD, FAANStudy Chair
Sites
10 total
Culver City, United StatesGarden Grove, United StatesLa Habra, United StatesSan Bernardino, United StatesSanta Ana, United StatesChicago, United StatesNew York, United StatesStaten Island, United StatesBeachwood, United StatesOklahoma City, United States
Facts & assertions
4 sourced
Enrollment
72
Phase
NA
Primary Completion Date
2022-09-22
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
company
indication
indication
indication
investigator